Kinase inhibitors and method of treating cancer with same

A compound represented by the following structural formula:

• or a pharmaceutically acceptable salt thereof, wherein:
• each R1 is independently selected from —H, -halogen, —CN, —NO2, ORc, —NRaRb, —S(O)iRc, —NRdS(O)iRc, —S(O)iNReRf, —C(═O)ORc, —OC(═O)ORc, —C(═S)ORc, —O(C═S)Rc, —C(═O)NReRf, —NRdC(═O)Rc, —C(═S)NReRf, —NRdC(═S)Rc, —NRd(C═O)ORc, —O(C═O)NReRf, —NRd(C═S)ORc, —O(C═S)NReRf, —NRd(C═O)NReRf, —NRd(C═S)NReRf, —C(═S)Rc, —C(═O)Rc, heterocycloalkyl, and alkyl, wherein the heterocycloalkyl or the alkyl is optionally substituted with 1 to 3 substituents independently selected from -halogen, —CN, —NO2, ORc, —NRaRb, —S(O)iRc, —NRdS(O)iRc, —S(O)iNReRf, —C(═O)ORc, —OC(═O)ORc, —C(═S)ORc, —O(C═S)Rc, —C(═O)NReRf, —NRdC(═O)Rc, —C(═S)NReRf, —NRdC(═S)Rc, —NRd(C═O)ORc, —O(C═O)NReRf, —NRd(C═S)ORc, —O(C═S)NReRf, —NRd(C═O)NReRf, —NRd(C═S)NReRf, —C(═S)Rc, and —C(═O)Rc;
• each R2 is independently selected from —(CH2)0-2C(═O)NR4(CH2)0-2Z—R5, —(CH2)0-2NR4C(═O)(CH2)0-2Z—R5, and —(CH2)0-2NR4(C═O)NR4(CH2)0-2Z—R5;
• X is —O—, —CR8R9—, —NR11—, or —S(O)i—;
• R4 is —H or an alkyl group optionally substituted with 1 to 3 substituents independently selected from halogen, hydroxy, and (C1-C3)alkoxy;
• R5 is alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each of which is optionally substituted with 1 to 3 groups individually represented by R15 or R16;
• Z is a bond or —CR13R14—;
• R6 and R6′ are each independently selected from halogen, hydroxy, (C1-C3)alkyl, (C1-C3)alkoxy, (C1-C3)alkyl-ORc, and —NRaRb;
• or two instances of R6 or R6′ on the same carbon are taken together form ═O;
• R8 and R9 are each independently selected from —H, —ORc, and (C1-C6)alkyl, wherein the (C1-C6)alkyl group is optionally substituted with 1 to 3 substituents independently selected from halogen, hydroxy, and (C1-C3)alkoxy;
• R11 is —H, (C1-C6)alkyl, cycloalkyl, cycloalkyl(C1-C6)alkyl, heterocycloalkyl, heterocycloalkyl(C1-C6)alkyl, —C(═O)Rc, or —C(═O)ORc, wherein each of the (C1-C6)alkyl, cycloalkyl, cycloalkyl(C1-C6)alkyl, heterocycloalkyl and heterocycloalkyl(C1-C6)alkyl groups is optionally substituted with 1 to 3 substituents independently selected from halogen, hydroxy, (C1-C3)alkoxy, and —C(═O)NReRf;
• R13 and R14 are each independently selected from —H, alkyl, —ORc, —NRaRb, —(C1-C3)alkylene-NRaRb, —(C1-C3)alkylene-ORc, —(C1-C3)alkylene-OH, cycloalkyl, —O-cycloalkyl, and heterocycloalkyl, wherein each of the cycloalkyl or heterocycloalkyl, groups is optionally substituted with 1 to 3 substituents independently selected from (C1-C3)alkyl and (C1-C3)alkoxy, provided that R13 and R14 are not both selected from —ORc and —NRaRb;
• R15 and R16 are each independently selected from halogen, —CN, —NO2, ═O, —ORc, —NRaRb, —S(O)iRc, —NRdS(O)iRc, —S(O)iNReRf, C(═O)ORc, —OC(═O)ORc, —C(═S)ORc, —O(C═S)Rc, —C(═O)NReRf, —NRdC(═O)Rc, —C(═S)NReRf, —NRdC(═S)Rc, —NRd(C═O)ORc, —O(C═O)NReRf, —NRd(C═S)ORc, —O(C═S)NReRf, —NRd(C═O)NReRf, —NRd(C═S)NReRf, —C(═S)Rc, —C(═O)Rc, (C1-C6)alkyl, aryl, aryl(C1-C3)alkyl, heterocycloalkyl and heteroaryl;
• wherein each (C1-C6)alkyl, aryl, aryl(C1-C3)alkyl, heterocycloalkyl and heteroaryl represented by R15 is optionally substituted with 1 to 3 substituents independently selected from -halogen, —CN, ORc, (C1-C6)alkyl, halo(C1-C6)alkyl, (C1-C3)alkoxy, halo(C1-C3)alkoxy, (C1-C3)alkoxy(C1-C6)alkyl, 3 to 8 membered heterocycloalkyl and 3 to 8 membered heteroaryl;
• Ra and Rb are each independently selected from —H and (C1-C6)alkyl, optionally substituted with 1 to 3 substituents independently selected from halogen, hydroxy, —NRgRh, and (C1-C3)alkoxy;
• Rc is —H or (C1-C6)alkyl, optionally substituted with 1 to 3 substituents independently selected from halogen, —NRgRh, hydroxy, and (C1-C3)alkoxy;
• Rd is —H or (C1-C6)alkyl, optionally substituted with 1 to 3 substituents independently selected from halogen, —NRgRh, hydroxy, and (C1-C3)alkoxy;
• Re and Rf are each independently selected from —H and (C1-C6)alkyl optionally substituted with 1 to 3 substituents independently selected from halogen, —NRgRh, hydroxy, and (C1-C3)alkoxy;
• or Re and Rf, together with the nitrogen to which they are attached, form a 3-8 membered ring optionally substituted with 1 to 3 substituents independently selected from halogen, —NRgRh, —CN, (C1-C6)alkyl, halo(C1-C6)alkyl, (C1-C3)alkoxy, halo(C1-C3)alkoxy, and (C1-C3)alkoxy(C1-C6)alkyl;
• Rg and Rh are each independently selected from —H, (C1-C6)alkyl, halo(C1-C6)alkyl, hydroxy(C1-C6)alkyl, and (C1-C3)alkoxy(C1-C6)alkyl;
• i is 0, 1, or 2;
• n is an integer from 1 to 4;
• m is an integer from 1 to 4;
• each of p1, p2, p1′, and p2′, independently, is 0, 1, 2, 3, or 4, provided that p1+p2 is greater than 1, and p1′+p2′ is greater than 1;
• q is 0, 1, or 2;
• and
• q′ is 0, 1, or 2.